Summary.-Previous studies, using plasmapheresis to remove blocking factors of cell-mediated cytotoxity to melanoma cells from the circulation of melanoma patients, suggested that leucocyte-dependent antibody to melanoma cells may also be blocked by factors in their sera. The present study confirms these findings, by showing that most patients with disseminated melanoma had melanoma LDA activity in the IgG fraction when this was separated from their sera. This also applied to a high percentage of patients with primary melanoma. Evidence that the blocking factors may be immune complexes was shown by experiments in which LDA activity to melanoma cells was revealed after acidification of melanoma sera to dissociate immune complexes, followed by ultrafiltration through membranes retaining molecules of size greater than 100,000 daltons. Blocking of LDA activity in the retentate recurred when the retentate was recombined with the filtrate. Further studies indicated that the blocking activity showed affinity for the target cell and not the effector cell. Preliminary analysis of the specificity of the blocking suggests that this was similar to that of melanoma antisera.
THE presence of blocking factors which inhibit cell-mediated cytotoxicity (CMC) against tumour cells appears to provide one of the more important mechanisms for escape of tumours from the immune cytotoxic response of the host. Serum factors having this activity have been demonstrated in both animal (Hellstr6m and Hellstrim, 1969; Sjogren, 1971, 1973; Robins, 1972, 1973; Thompson, Eccles and Alexander, 1973) and human studies (Hellstrom et al., 1971; Currie and Basham, 1972; Baldwin, Embleton and Price, 1973; Jose and Seshadri, 1974) . In particular, studies on melanoma subjects appear to confirm the importance of these factors by demonstrating a good correlation between the presence of blocking factors of CMC in the sera of melanoma patients and the clinical course of tumour growth (Hellstrom and Hellstr6m, 1973; Hellstrom et al., 1973) .
During recent studies designed empirically to remove blocking factors of CMC from the circulation of melanoma patients by plasmapheresis, it was noted that antibodies which could induce leucocytedependent killing of melanoma cells (leucocyte-dependent antibody, LDA) appeared in their sera after the plasmapheresis procedure (Hersey et al., 1976a) . This suggested that LDA activity was blocked by factors in the sera of melanoma patients similar to that proposed for direct CMC, and that these phenomena may be of equal importance in allowing escape of the tumour cells from the immune cytotoxic response of the host.
In this report we present evidence, from in vitro studies, for the presence of serum blocking factors against melanoma LDA, based on LDA assays of fractions of sera obtained by column chromatography and by dissociation and ultrafiltration of melanoma sera. Our results suggest that "masking" of LDA activity may be the usual finding in patients with disseminated melanoma.
MATERIALS AND METHODS
Patients.-Sera were taken from patients with melanoma attending the Melanoma Unit, Sydney Hospital. H.I. and C.H. were patients with disseminated melanoma who had shown clinical improvement after surgery and chemo-immunotherapy and had no clinically detectable tumour. Patients J.S., C.Q., M.T., D.R., H.F. and B.N. had clinic ally evident disseminated melanoma. Patients B., R.G., N.D., R.L., D.T., M.C., A. and M. had primary melanoma which was subsequently removed surgically. Sera were from defibrinated blood samples and were stored at -20°C in 2-3-ml-aliquots until use.
Gel exclusion chromatography.-Whole sera were separated into several fractions on the basis of molecular size using Sepharose CL-6B (Pharmacia) in a column 2-6 x 70 cm (Type K26/70, Pharmacia). Two ml of whole serum was applied to the column and eluted with 0.9% saline containing 0.02% sodium azide by upward flow at a rate of 0 5 ml/min at 4C. Fifty fractions of 6 ml each were collected.
U.v. absorbance of the fractions was measured at 280 nm on a Unicam SP1800 u.v. spectrophotometer, and the fractions were pooled into 4 groups according to molecular size, on the basis of chromatogram results. The large mol. wt fractions were concentrated back to 2 ml in an Amicon Diaflo cell, using an XM100-A membrane, and the small mol. wt fraction using a UM-2 membrane. They were then dialysed twice against 500 ml 0-9% NaCl. Immunoglobulins in each were identified by immunodiffusion on Tri-Partigen plates (Hoechst).
Low-pH dissociation and ultrafiltration of whole sera.-A modification of the method described by Sjogren et al. (1971) (Hersey et al., 1976b LDA assays.-Fractions obtained by the chromatography procedures described, or by low-pH dissociation and ultrafiltration, were assayed for LDA by addition of 100 dul of the fraction at the dilutions indicated to cultures containing 5 x 103 in 500 jul of 5'Cr-labelled TCs (usually MM 200). This was followed by the addition of 5 x 105 effector cells in 500 pI. The cultures were in duplicate (12 x 75) mm round-bottomed plastic tubes (Sterilin, Filtrona, Melbourne). The tubes were capped and incubated overnight for 16 h at 37°C in 7% Co2 in air. Assays were terminated by centrifugation for 7 min at 400 g, and 500 jA of the supernatant removed for estimation of 5'Cr release. Samples were counted in an automatic Wallac 1280 gamma counter.
Percent 5'Cr release was estimated by the formula a x 2-2 X~1 I00
test blocking material. (Where the added test fractions had LDA activity, the baseline was taken as for A above). In experiments to test for affinity of blocking activity to target cells, or inhibitory activity to effector cells, 100 jA of the test material was added to either target cell or effector cell for 1 h at room temperature, anld the tubes were then washed twice in 5 ml of MEM. The tubes were drained and 100 t,l of sensitizing IgG melanoma antibody added, together with the effector cells in 1 ml of medium. In these experiments control cultures not exposed to the test material were subjected to a similar washing procedure in parallel with the test cultures.
Statistical analysis-.Student's t test was
used to compare the percent 5'Cr release of cultures with and without LDA activity, and to compare LDA activity in the presence or absence of added blocking factors. Findings were considered significant when P < 0 05.
where a= 5'Cr counts in the supernatantbackground count, and b = counts in tube with remaining supernatant and cells-background counts. The LDA titre of sera or fractions of sera was taken as the last dilution giving 5% 5'Cr release above the baseline release of target cells and effector cells in the absence of added sera or sera fractions. This level of 5'Cr release was about 2 standard errors from the points concerned, and was taken as the minimum definite evidence of LDA activity in the test.
Blocking of LDA assays.-Sera were tested for blocking of LDA activity by addition to cultures containing IgG known to induce LDA reactivity against melanoma cells. 100 ,ul of the serum to be tested for blocking activity was added to the TCs, followed by 100 dul of the sensitizing IgG antibody and 5 x 105 effector cells in 500 y1. Incubation was carried out overnight and percent 5'Cr release estimated as above, except that the multiplication factor for "a" was 2-4. The percentage inhibition or blocking of the antibody-dependent killing was estimated by the formula A-B Footnote: Spontaneous 5"Cr release from TCs ranged from 22 to 38%. 51Cr release due to cytotoxicity of effector cells ranged from 5 to 15% above spontaneous release (see Fig. 1 The results in Table II indicate similar studies on sera from 4 patients with disseminated melanoma, 2 normal subjects and 4 non-melanoma carcinoma subjects. All of the melanoma sera had LDA activity in the retained fraction after dissociation and ultrafiltration, but sera from the other subjects did not. Also illustrated in the Table are control studies showing that no LDA activity was seen when the ultrafiltration was carried out after restoration of the pH to 7-4, or when saline instead of the glycine buffer at pH 2-8 was added to the serum. Only slight activity was seen when ultrafiltration of the acidified serum was carried out through membranes retaining (1) pH restor-ed to 7-4 before tultrafiltrationi, (2) Ultrafiltration throuigh PM-10 instead of XM-100 membianes, (3) Ultrafiltration after ad(ition of saline instea(d of glycine buffer at pH 2-8
See also footnote to Table 1. molecules greater than I 0,000d, indicating that the blocking factors were between 10,000 and 100,OOOd.
Titration of blocking activity and affinity of blocking activity for target cells or effector cells Experiments were conducted to determine the titre of blocking activity and whether the blocking activity was directed to the target cell or the effector cells. One such experiment is illustrated in Fig. 3 , in which serum from Subject G.Q. was added to MM 200 TCs sensitized with a constant amount of the IgG fraction from G.Q. Significant blocking activity was still present at a titration of 1/104 of the serum when present throughout the culture period. When the blocking serum was added to the target cells and washed, marked inhibition of the LDA activity of added IgG was still shown. Blocking was less marked however when the serum was added to the effector cells and washing carried out.
Similar results to those illustrated in Fig. 3 are shown in Table III . In all experiments, the blocking activity of the sera showed affinity for the target cell Specificity of the blocking activity of melanoma To determine the broad specificity of the blocking activity to melanoma, sera from patients with disseminated melanoma were added to cultures of Chang cells sensitized with rabbit anti-Chang serum (Hersey, Edwards and Edwards, 1976) . As shown in Table IV , no blocking of the killing of sensitized Chang cells by leucocytes was seen. This applied even when the IgG fraction from the melanoma patient was present as well.
Initial studies to determine the specificity of the blocking activity between different melanoma patients are also shown in Table IV 
DISCUSSION
From these initial studies it appears that masking of LDA activity is a common finding in the sera of patients with advanced melanoma, and to a lesser extent in patients with primary melanoma. This has been demonstrated by several methods, including separation of the IgG fraction from sera by gel chromatography, and acidification and ultrafiltration of melanoma sera to dissociate and separate immune complexes, similar studies to those previously described by Sjogren et al. (1971 Sjogren et al. ( , 1972 . In view of the suggested biological importance of LDA in tumour rejection (Lamon et al., 1973; Hersey, 1973; O'Toole et al., 1974 ) the presence of these blocking factors against LDA may be an important factor in allowing escape of the tumour cells from this immune cytotoxic mechanism.
The specificity of the LDA activity detected in these sera has not yet been extensively studied. However, none of the melanoma sera or sera fractions reacted with the control Chang liver cell, and 3 of the strongly positive 7s fractions from melanoma sera did not react with ovarian carcinoma cells in culture. Perhaps more importantly, we have not shown LDA activity in the IgG-containing fractions of sera from 7 normal subjects and 6 patients with various malignancies other than melanoma. This suggests that the LDA activity revealed in the 7s fractions of melanoma sera is related to melanoma. From our previous studies on the specificity of LDA found in melanoma sera, some reactivity against non-melanoma cells may be expected on the basis of cross-reacting foetal antigens (Hersey et al., 1976b) .
Several other questions arise from these studies. One concerns the nature of the blocking activity detected in these assays. In common with the findings of Sjogren et al. (1971 Sjogren et al. ( , 1972 in studies on blocking of direct CMC to tumour cells, we have found that the blocking activity against melanoma LDA can be dissociated into large-and small-mol.-wt components and that the small-mol.-wt component was between 10,000 and 100,000 daltons. This evidence suggested that immune complexes were involved and that the small-mol.-wt component may be tumour antigen. The size of the antigen in these studies would be consistent with that described for melanoma antigens by Currie (1973) .
The second question relating to these studies is the specificity of the blocking activity. The results above indicate that the blocking activity in the sera tested was directed to the target cell and not the effector cells. This was further shown by the studies in which no blocking was seen when the sera were added to LDA assays of Chang cells sensitized with rabbit antiChang serum. This latter test system was shown previously to be inhibited nonspecifically by immune complexes interacting with the effector cells (MacLennan, 1972) . it was found in these studies that complexes in slight antigen excess showed maximum inhibition, and that complexes in antibody excess had little or no inhibitory activity. Our results therefore suggest that if immune complexes are responsible for the blocking activity they are probably in antibody excess. This would explain the absence of non-specific blocking of LDA activity and the specificity of the blocking activity for the target cells. If this is so, it can be expected that the specificity of blocking will be similar to that described in our previous studies (Hersey et al., 1976b) in which limited cross-reactivity of antisera between different individuals with melanoma was found.
The findings above appear to provide an analytical assay system which we anticipate may be useful in further characterizing blocking factors. Preliminary results of work in progress also suggest that the measurement of blocking activity against melanoma LDA may be of value in monitoring patients with melanoma.
